NASDAQ:CRBU Caribou Biosciences (CRBU) Stock Price, News & Analysis $1.84 +0.04 (+2.22%) Closing price 08/21/2025 04:00 PM EasternExtended Trading$1.82 -0.02 (-1.09%) As of 07:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Caribou Biosciences Stock (NASDAQ:CRBU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Caribou Biosciences alerts:Sign Up Key Stats Today's Range$1.74▼$1.8450-Day Range$1.11▼$2.4852-Week Range$0.66▼$3.00Volume563,033 shsAverage Volume1.35 million shsMarket Capitalization$171.34 millionP/E RatioN/ADividend YieldN/APrice Target$6.67Consensus RatingBuy Company Overview Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. Read More Caribou Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreCRBU MarketRank™: Caribou Biosciences scored higher than 57% of companies evaluated by MarketBeat, and ranked 438th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCaribou Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCaribou Biosciences has received no research coverage in the past 90 days.Read more about Caribou Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.64) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caribou Biosciences is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Caribou Biosciences is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCaribou Biosciences has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Caribou Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.82% of the float of Caribou Biosciences has been sold short.Short Interest Ratio / Days to CoverCaribou Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caribou Biosciences has recently decreased by 15.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaribou Biosciences does not currently pay a dividend.Dividend GrowthCaribou Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.82% of the float of Caribou Biosciences has been sold short.Short Interest Ratio / Days to CoverCaribou Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caribou Biosciences has recently decreased by 15.58%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.40 News SentimentCaribou Biosciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Caribou Biosciences this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Caribou Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.28% of the stock of Caribou Biosciences is held by insiders.Percentage Held by Institutions77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Caribou Biosciences' insider trading history. Receive CRBU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBU Stock News HeadlinesCaribou Biosciences (NASDAQ:CRBU) Downgraded to Sell Rating by Wall Street ZenAugust 18, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for CRBU FY2025 Earnings?August 17, 2025 | americanbankingnews.comOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from a $63,000 luxury… into a 90-cent mass production reality. It’s 400x stronger than steel, conducts electricity better than copper… and just saved 379 lives in a single plane crash.August 22 at 2:00 AM | True Market Insiders (Ad)CRBU Q3 EPS Forecast Boosted by Brookline Capital ManagementAugust 17, 2025 | americanbankingnews.comCaribou Biosciences reports Q2 EPS (35c), one estimate (42c)August 12, 2025 | msn.comCaribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comCARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJuly 25, 2025 | globenewswire.comCaribou Biosciences: Key Data Updates Coming, But I'm Concerned About Near-Term VolatilityJuly 17, 2025 | seekingalpha.comSee More Headlines CRBU Stock Analysis - Frequently Asked Questions How have CRBU shares performed this year? Caribou Biosciences' stock was trading at $1.59 at the start of the year. Since then, CRBU stock has increased by 15.7% and is now trading at $1.84. How were Caribou Biosciences' earnings last quarter? Caribou Biosciences, Inc. (NASDAQ:CRBU) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. The firm had revenue of $2.67 million for the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative trailing twelve-month return on equity of 62.35% and a negative net margin of 1,800.93%. When did Caribou Biosciences IPO? Caribou Biosciences (CRBU) raised $202 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 13,500,000 shares at a price of $14.00-$16.00 per share. Who are Caribou Biosciences' major shareholders? Caribou Biosciences' top institutional investors include Geode Capital Management LLC (1.05%), Aberdeen Group plc (0.97%), Bank of America Corp DE (0.87%) and Pale Fire Capital SE (0.83%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Steven Kanner, Ryan Fischesser, Syed Ali-Aamir Rizvi and Sriram Ryali. View institutional ownership trends. How do I buy shares of Caribou Biosciences? Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Caribou Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/12/2025Today8/21/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBU CIK1619856 Webcariboubio.com Phone510-982-6030FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Caribou Biosciences$6.67 High Price Target$11.00 Low Price Target$3.00 Potential Upside/Downside+262.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$149.10 million Net Margins-1,800.93% Pretax Margin-1,801.03% Return on Equity-62.35% Return on Assets-49.65% Debt Debt-to-Equity RatioN/A Current Ratio6.66 Quick Ratio6.66 Sales & Book Value Annual Sales$9.99 million Price / Sales17.15 Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book1.03Miscellaneous Outstanding Shares93,120,000Free Float85,412,000Market Cap$171.34 million OptionableOptionable Beta2.55 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CRBU) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.